Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Tokyo Stock Exchange  >  Daiichi Sankyo Company, Limited    4568   JP3475350009

DAIICHI SANKYO COMPANY, LIMITED

(4568)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Tokyo Stock Exchange
09/17/2020 09/18/2020 09/23/2020 09/24/2020 09/25/2020 Date
9997 9657 9762 9732 9756 Last
556800 1910000 1073800 712600 802700 Volume
-0.63% -3.40% +1.09% -0.31% +0.25% Change
Financials
Sales 2021 968 B 9 177 M 9 177 M
Net income 2021 66 740 M 632 M 632 M
Net cash position 2021 575 B 5 453 M 5 453 M
P/E ratio 2021 94,9x
Yield 2021 0,81%
Sales 2022 1 027 B 9 731 M 9 731 M
Net income 2022 87 336 M 828 M 828 M
Net cash position 2022 612 B 5 803 M 5 803 M
P/E ratio 2022 72,9x
Yield 2022 0,80%
Capitalization 6 323 B 59 853 M 59 912 M
EV / Sales 2021 5,93x
EV / Sales 2022 5,56x
Nbr of Employees 15 348
Free-Float 90,5%
More Financials
Company
Daiichi Sankyo Company specializes in developing, manufacturing and marketing pharmaceutical products. Net sales break down by activity as follows: - sale of medicines (99.8%): prescription medicines (92.8% of net sales) and OTC medicines (7.2%) primarily for the treatment of thrombotic disorders, tumors, diabetes and rheumatoid arthritis; - other (0.2%): primarily real estate activities. Net sales are... 
More about the company
Notations Surperformance© of Daiichi Sankyo Company, Limited
Trading Rating : Investor Rating :
More Ratings
All news about DAIICHI SANKYO COMPANY, LIMITED
09/25DAIICHI SANKYO : Announces Establishment of DAIICHI SANKYO VIETNAM COMPANY LIMIT..
AQ
09/14Gilead bolsters cancer portfolio with $21 billion acquisition of Immunomedics
RE
09/14DAIICHI SANKYO : Submits Supplemental Application in Japan for Approval of Parti..
AQ
09/14Gilead bolsters cancer portfolio with $21 bln acquisition of Immunomedics
RE
09/07DAIICHI SANKYO : AnHeart Licenses Two Clinical Stage Oncology Candidates from Da..
AQ
09/04Astrazeneca to begin Phase 1/2 clinical trials of coronavirus vaccine in Japa..
RE
09/01DAIICHI SANKYO : Announces Results of Phase 3 Clinical Trial for Anticoagulant E..
AQ
09/01DAIICHI SANKYO : Selected for AMED's 'Development of a Vaccine for COVID-19 Vacc..
AQ
08/31DAIICHI SANKYO : COVID-19 vaccine selected by Japanese drug discovery body
RE
08/31Daiichi sankyo's mrna covid-19 vaccine selected for second round by japan's a..
RE
08/28Japan, eyeing Olympics, lines up half-billion doses of COVID-19 vaccine
RE
08/17Japanese stocks slip as economy shrinks at record rate on pandemic hit
RE
08/10DAIICHI SANKYO : Announces Clinical Trial Collaboration with AstraZeneca to Eval..
AQ
08/10DAIICHI SANKYO : Selected as Provider for Japanese Government's 'Emergent Initia..
AQ
08/07Japan in deals with AstraZeneca, Novavax for COVID-19 vaccines
RE
More news
News in other languages on DAIICHI SANKYO COMPANY, LIMITED
09/14US-Biotechkonzern Gilead stärkt Krebsgeschäft mit Milliardenzukauf
09/04CORONAVIRUS : Astrazeneca lance la 1ère phase de l'essai clinique de son vaccin ..
08/06VALNEVA nomme un Directeur Médical
08/06VALNEVA : nouveau directeur médical début octobre
07/28ASTRAZENECA : dans le vert après l'analyse de Crédit Suisse
More news
Chart DAIICHI SANKYO COMPANY, LIMITED
Duration : Period :
Daiichi Sankyo Company, Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends DAIICHI SANKYO COMPANY, LIMITED
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 12
Average target price 9 541,67 JPY
Last Close Price 9 756,00 JPY
Spread / Highest target 33,3%
Spread / Average Target -2,20%
Spread / Lowest Target -26,2%
EPS Revisions
Managers
NameTitle
Sunao Manabe President, CEO & Representative Director
Toshiaki Sai CFO, Representative Director & Executive VP
Wataru Takasaki Executive Officer, GM-Research & Development
Noritaka Uji Independent Outside Director
Satoru Kimura Director & General Manager-Pharmaceutical Sales
Sector and Competitors
1st jan.Capitalization (M$)
DAIICHI SANKYO COMPANY, LIMITED34.98%59 853
JOHNSON & JOHNSON-0.14%383 497
ROCHE HOLDING AG5.40%304 339
MERCK & CO., INC.-8.82%209 750
PFIZER, INC.-8.73%200 326
NOVARTIS AG-12.61%190 402